WO2000060051A8 - Arpe-19 as a platform cell line for encapsulated cell-based delivery - Google Patents

Arpe-19 as a platform cell line for encapsulated cell-based delivery

Info

Publication number
WO2000060051A8
WO2000060051A8 PCT/US2000/009150 US0009150W WO0060051A8 WO 2000060051 A8 WO2000060051 A8 WO 2000060051A8 US 0009150 W US0009150 W US 0009150W WO 0060051 A8 WO0060051 A8 WO 0060051A8
Authority
WO
WIPO (PCT)
Prior art keywords
arpe
cell line
cell
based delivery
encapsulated
Prior art date
Application number
PCT/US2000/009150
Other languages
French (fr)
Other versions
WO2000060051A2 (en
WO2000060051A3 (en
Inventor
Weng Tao
David H Rein
Brenda J Dean
Paul F Stabila
Moses B I Goddard
Original Assignee
Neurotech Sa
Weng Tao
David H Rein
Brenda J Dean
Paul F Stabila
Moses B I Goddard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00923144A priority Critical patent/EP1171573B1/en
Priority to JP2000609543A priority patent/JP4954374B2/en
Priority to BRPI0009562-1A priority patent/BR0009562A/en
Priority to DE60011761T priority patent/DE60011761T2/en
Application filed by Neurotech Sa, Weng Tao, David H Rein, Brenda J Dean, Paul F Stabila, Moses B I Goddard filed Critical Neurotech Sa
Priority to US09/958,040 priority patent/US7115257B1/en
Priority to AU43319/00A priority patent/AU773387B2/en
Priority to CA2365532A priority patent/CA2365532C/en
Priority to AT00923144T priority patent/ATE269715T1/en
Publication of WO2000060051A2 publication Critical patent/WO2000060051A2/en
Publication of WO2000060051A8 publication Critical patent/WO2000060051A8/en
Priority to NO20014856A priority patent/NO20014856D0/en
Publication of WO2000060051A3 publication Critical patent/WO2000060051A3/en
Priority to US11/543,015 priority patent/US20070071734A1/en
Priority to US12/498,737 priority patent/US20090269389A1/en
Priority to US12/499,403 priority patent/US20090269319A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; has a long life span; is of human origin; has good in vivo device viability; delivers efficacious quantity of growth factor; triggers no or low level host immune reaction, and is non-tumorigenic.
PCT/US2000/009150 1999-04-06 2000-04-06 Arpe-19 as a platform cell line for encapsulated cell-based delivery WO2000060051A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU43319/00A AU773387B2 (en) 1999-04-06 2000-04-06 ARPE-19 as a platform cell line for encapsulated cell-based delivery
BRPI0009562-1A BR0009562A (en) 1999-04-06 2000-04-06 arp- 19 as an encapsulated cell-based release platform cell line
DE60011761T DE60011761T2 (en) 1999-04-06 2000-04-06 ARPE-19 AS PLATFORM CELL LINE FOR THE ADMINISTRATION OF ENCAPSULATED CELLS
AT00923144T ATE269715T1 (en) 1999-04-06 2000-04-06 ARPE-19 AS A CELL LINE PLATFORM FOR ADMINISTRATION OF ENCAPSULATED CELLS
US09/958,040 US7115257B1 (en) 1999-04-06 2000-04-06 ARPE-19 as a platform cell line for encapsulated cell-based delivery
JP2000609543A JP4954374B2 (en) 1999-04-06 2000-04-06 ARPE-19 as a platform cell line for encapsulated cell-based delivery
CA2365532A CA2365532C (en) 1999-04-06 2000-04-06 Arpe-19 as a platform cell line for encapsulated cell-based delivery
EP00923144A EP1171573B1 (en) 1999-04-06 2000-04-06 Arpe-19 as a platform cell line for encapsulated cell-based delivery
NO20014856A NO20014856D0 (en) 1999-04-06 2001-10-05 ARPE-19 as a platform cell line for encapsulated cell-based delivery
US11/543,015 US20070071734A1 (en) 1999-04-06 2006-10-03 ARPE-19 as platform cell line for encapsulated cell-based delivery
US12/498,737 US20090269389A1 (en) 1999-04-06 2009-07-07 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
US12/499,403 US20090269319A1 (en) 1999-04-06 2009-07-08 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12792699P 1999-04-06 1999-04-06
US60/127,926 1999-04-06
US09/543,119 US6361771B1 (en) 1999-04-06 2000-04-05 ARPE-19 as a platform cell line for encapsulated cell-based delivery
US09/543,119 2000-04-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/543,015 Continuation US20070071734A1 (en) 1999-04-06 2006-10-03 ARPE-19 as platform cell line for encapsulated cell-based delivery

Publications (3)

Publication Number Publication Date
WO2000060051A2 WO2000060051A2 (en) 2000-10-12
WO2000060051A8 true WO2000060051A8 (en) 2001-04-05
WO2000060051A3 WO2000060051A3 (en) 2002-03-28

Family

ID=26826092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009150 WO2000060051A2 (en) 1999-04-06 2000-04-06 Arpe-19 as a platform cell line for encapsulated cell-based delivery

Country Status (12)

Country Link
US (2) US6361771B1 (en)
EP (1) EP1171573B1 (en)
JP (2) JP4954374B2 (en)
AT (1) ATE269715T1 (en)
AU (1) AU773387B2 (en)
BR (1) BR0009562A (en)
CA (1) CA2365532C (en)
DE (1) DE60011761T2 (en)
DK (1) DK1171573T3 (en)
ES (1) ES2219335T3 (en)
NO (1) NO20014856D0 (en)
WO (1) WO2000060051A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878544B2 (en) * 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2003033016A1 (en) * 2001-10-16 2003-04-24 Jenny Phipps Use of neurotrophic factors for treating neurodegenerative diseases and cancer
WO2003092728A1 (en) * 2002-04-30 2003-11-13 Canadian Blood Services Encapsulated cells to elicit immune response
JP4571776B2 (en) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 Lubricating oil composition
CA2522364C (en) 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
AU2004245175C1 (en) * 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
US8257963B2 (en) 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
US7897384B2 (en) * 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7927599B2 (en) * 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
JP2007509109A (en) 2003-10-20 2007-04-12 エヌエスジーン・アクティーゼルスカブ In vivo gene therapy for Parkinson's disease
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
CN101123978B (en) 2004-08-19 2012-12-12 比奥根艾迪克Ma公司 Neublastin variants
EP2238983B1 (en) * 2004-08-19 2014-07-23 Biogen Idec MA Inc. Neublastin variants
MX2007012155A (en) * 2005-04-01 2008-04-04 Nsgene As A human immortalised neural precursor cell line.
US9364427B2 (en) * 2005-05-17 2016-06-14 Nsgene A/S Implantable therapy system for treating a living being with an active factor
US20080260702A1 (en) * 2005-10-11 2008-10-23 Jesper Roland Jorgensen Treatment of Retinopathies Using Gfra3 Agonists
US20080286250A1 (en) * 2005-10-28 2008-11-20 Jens Tornoe Implantable Biocompatible Immunoisolatory Vehicle for Delivery of Gdnf
ES2406716T3 (en) * 2005-12-30 2013-06-07 Neurotech Usa, Inc. Micronized device for the supply of biologically active molecules and method of use thereof
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
ES2450065T3 (en) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Compositions and methods for the administration of GDNF ligand family proteins
JP5583005B2 (en) * 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Compositions and methods for increasing angiogenesis
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
US8075537B2 (en) * 2008-08-15 2011-12-13 Oxyband Technologies, Inc. Multiple cell therapeutic diffusion device
EP2389435B1 (en) * 2009-01-23 2015-11-04 NsGene A/S Improved cell lines and their use in encapsulated cell biodelivery
US20120021039A1 (en) 2009-01-23 2012-01-26 Nsgene A/S Expression of neuropeptides in mammalian cells
EP2421981B1 (en) * 2009-04-23 2013-08-14 Neurotech USA, Inc. Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof
US20110111008A1 (en) * 2009-10-08 2011-05-12 Weng Tao Use of PEDF in an Encapsulated Cell-Based Delivery System
US20110104154A1 (en) * 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
EP2593117B1 (en) 2010-07-12 2019-03-20 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
AU2011336592A1 (en) 2010-12-02 2013-07-11 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
WO2012149468A2 (en) 2011-04-29 2012-11-01 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US9265813B2 (en) 2011-10-27 2016-02-23 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
KR20150016367A (en) 2012-05-30 2015-02-11 뉴로테크 유에스에이, 인코포레이티드. Cryopreserved implantable cell culture devices and uses thereof
WO2014200997A2 (en) * 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Method for preparing three-dimensional, organotypic cell cultures and uses thereof
CA2922483A1 (en) 2013-09-11 2015-03-19 Neurotech Usa, Inc. Encapsulated cell therapy cartridge
FR3014316B1 (en) * 2013-12-10 2017-01-20 Defymed BIOARTIFICIAL ORGAN
WO2016036322A1 (en) 2014-09-04 2016-03-10 Kemijski inštitut Cell-based device for local treatment with therapeutic protein
WO2016191645A1 (en) * 2015-05-27 2016-12-01 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
EP4051192A1 (en) 2019-11-01 2022-09-07 Neurotech USA, Inc. System, apparatuses, devices, and methods for an analyte diffusive implantable device
WO2021204935A1 (en) 2020-04-09 2021-10-14 Defymed Membranes for medical devices
EP3892259A1 (en) 2020-04-09 2021-10-13 Defymed Membranes for medical devices
WO2022011081A1 (en) 2020-07-09 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell lines that produce human retinoschisin proteins and uses thereof
WO2022233989A1 (en) 2021-05-06 2022-11-10 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
DE3829752A1 (en) 1988-09-01 1990-03-22 Akzo Gmbh INTEGRAL ASYMMETRICAL POLYAETHERSULPHONE MEMBRANE, METHOD FOR THE PRODUCTION AND USE FOR ULTRAFILTRATION AND MICROFILTRATION
DE3829766A1 (en) 1988-09-01 1990-03-22 Akzo Gmbh METHOD FOR PRODUCING MEMBRANES
DK0585368T3 (en) 1991-04-25 1998-03-16 Univ Brown Res Found Implantable biocompatible immuno-insulating vehicle for delivery of selected therapeutic products
FR2681609B1 (en) 1991-09-24 1994-12-30 Centre Nat Rech Scient LINES OF IMMORTALIZED CEREBRAL ENDOTHELIAL CELLS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS A STUDY MODEL OF CEREBRAL PHYSIOPATHOLOGY.
EP0653943A4 (en) 1992-07-13 1996-10-02 Baylor College Medicine Targeting somatic gene therapy to joints.
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
EP0708670A4 (en) 1993-06-23 1998-07-01 Cytotherapeutics Inc Method and apparatus for sealing implantable, membrane encapsulation devices
ES2178654T3 (en) 1993-08-12 2003-01-01 Neurotech Sa IMMONO-ISOLATED BIOCOMPATIBLE CAPSULES CONTAINING GENETICALLY ALTERED CELLS FOR THE SUPPLY OF BIOLOGICALLY ACTIVE MOLECULES.
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6020192A (en) * 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery

Also Published As

Publication number Publication date
US7115257B1 (en) 2006-10-03
AU4331900A (en) 2000-10-23
ES2219335T3 (en) 2004-12-01
ATE269715T1 (en) 2004-07-15
DE60011761D1 (en) 2004-07-29
WO2000060051A2 (en) 2000-10-12
DK1171573T3 (en) 2004-09-27
EP1171573B1 (en) 2004-06-23
BR0009562A (en) 2007-05-29
CA2365532A1 (en) 2000-10-12
AU773387B2 (en) 2004-05-27
JP2003524621A (en) 2003-08-19
JP2011074079A (en) 2011-04-14
WO2000060051A3 (en) 2002-03-28
US6361771B1 (en) 2002-03-26
CA2365532C (en) 2012-11-06
DE60011761T2 (en) 2005-08-04
NO20014856D0 (en) 2001-10-05
JP4954374B2 (en) 2012-06-13
EP1171573A1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
WO2000060051A3 (en) Arpe-19 as a platform cell line for encapsulated cell-based delivery
ES2054614T3 (en) NEW IMMOBILIZED BIOCATALIZERS, THEIR PREPARATION AND APPLICATION.
WO2000056861A8 (en) Methods of microencapsulating pancreatic islet cells
WO1997042975A3 (en) Chitosan related compositions for delivery of nucleic acids into a cell
WO2000006704A3 (en) Hematopoietic cell composition for use in transplantation
WO2000002999A3 (en) Medium and matrix for long-term proliferation of cells
EP0171710A3 (en) Process for preparing liposome composition
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
AU5590586A (en) Non dusty blends of meals or flours with active principles for use in fodder production
CA2250880A1 (en) Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
AU1502695A (en) Double stranded RNA correction of abherrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
AU4765999A (en) Polyionic hydrogels based on xanthan and chitosan for stabilising and controlledrelease of vitamins
WO2000066158A3 (en) Use of cytokines and mitogens to inhibit pathological immune responses
FR2598591B1 (en) PROCESS FOR THE CULTURE OF PROCARYOYES AND EUKARYOTES AND USE OF THE CELLS THUS PREPARED IN COSMETIC, FOOD COMPOSITIONS AND FORAGE SUPPLEMENTS
WO2001029070A8 (en) Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
YAMADA et al. Developmental changes in the sucrase-isomaltase complex in rat intestinal mucosa
EP0314042A3 (en) Novel copolymers and superoxide dismutase modified with said copolymers
ES2132027A1 (en) Development of an artificial skin by means of keratinocyte culture on a base of fibrin and human fibroblasts, and method for preparing this skin for transplantation
EP1154801A4 (en) Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
AU1232399A (en) Inducible cellular immunity through activation of th1 and suppression of th2 responses by macrophages
WO2002050243A3 (en) The use of ecm degrading enzymes for the improvement of cell transplantation
Fernandez Mecanismes d'agressio de la cellula beta pancreatica: Reparacio nuclear.
EP0291164A3 (en) Growth-suppressing infusion medium, growth-suppressing cell culture medium and processes for the suppression of transformed cell growth
He et al. The Effect of Cu super (2+) and Zn super (2+) Stress on Antioxidant Enzyme Activity and Lipid Peroxidation Level of Entomogenous Fungal Species Cordyceps Militaris
Le Cohu et al. Gonyostomum semen, a Potential Nuisance in Large French Reservoirs. The Case of the Pareloup Lake(Gonyostomum semen(Raphidophycees), Nuisance Potentielle des Grands Reservoirs Francais. L'exemple du Lac de Pareloup)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 41/2000 UNDER (30) AND (63) REPLACE "NOT FURNISHED" BY "09/543119"

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2365532

Country of ref document: CA

Ref country code: CA

Ref document number: 2365532

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609543

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923144

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2000923144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09958040

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWG Wipo information: grant in national office

Ref document number: 2000923144

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0009562

Country of ref document: BR